MedTrace Logo

Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma

NCT05113615 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-05-23

No results posted yet for this study

Summary

The study will assess if regular use of tiotropium (i.e. daily) results in loss of bronchoprotection against methacholine induced bronchoconstriction in those with mild asthma.

Conditions

Interventions

DRUG

Tiotropium Bromide

respimat inhaler 2.5mcg/puff

DRUG

Matching placebo

matching placebo Respimat inhaler

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Don Cockcroft, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2022-05-06
Completion
2022-05-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05113615 on ClinicalTrials.gov